Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Dominique Baeten, Joachim Sieper, J. Braun, et al.
New England Journal of Medicine (2015) Vol. 373, Iss. 26, pp. 2534-2548
Open Access | Times Cited: 903

Showing 1-25 of 903 citing articles:

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
Désirée van der Heijde, Sofía Ramiro, Robert Landewé, et al.
Annals of the Rheumatic Diseases (2017) Vol. 76, Iss. 6, pp. 978-991
Open Access | Times Cited: 1449
The IL-17 Family of Cytokines in Health and Disease
Mandy J. McGeachy, J. Daniel, Sarah L. Gaffen
Immunity (2019) Vol. 50, Iss. 4, pp. 892-906
Open Access | Times Cited: 1088
Axial spondyloarthritis
Joachim Sieper, Denis Poddubnyy
The Lancet (2017) Vol. 390, Iss. 10089, pp. 73-84
Closed Access | Times Cited: 1073
Ankylosing Spondylitis and Axial Spondyloarthritis
Joel D. Taurog, Avneesh Chhabra, Robert A. Colbert
New England Journal of Medicine (2016) Vol. 374, Iss. 26, pp. 2563-2574
Closed Access | Times Cited: 738
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Michael M. Ward, Atul Deodhar, Lianne S. Gensler, et al.
Arthritis Care & Research (2019) Vol. 71, Iss. 10, pp. 1285-1299
Open Access | Times Cited: 530
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Michael M. Ward, Atul Deodhar, Lianne S. Gensler, et al.
Arthritis & Rheumatology (2019) Vol. 71, Iss. 10, pp. 1599-1613
Open Access | Times Cited: 526
Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management
Gerhard Rogler, Abha G. Singh, Arthur Kavanaugh, et al.
Gastroenterology (2021) Vol. 161, Iss. 4, pp. 1118-1132
Open Access | Times Cited: 514
Interleukin 17 is a chief orchestrator of immunity
Marc Veldhoen
Nature Immunology (2017) Vol. 18, Iss. 6, pp. 612-621
Closed Access | Times Cited: 415
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Kamran Ghoreschi, Anna Balato, Charlotta Enerbäck, et al.
The Lancet (2021) Vol. 397, Iss. 10275, pp. 754-766
Closed Access | Times Cited: 404
Ankylosing spondylitis: etiology, pathogenesis, and treatments
Wei Zhu, Xuxia He, Kai-Yuan Cheng, et al.
Bone Research (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 371
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
Désirée van der Heijde, Atul Deodhar, James Cheng‐Chung Wei, et al.
Annals of the Rheumatic Diseases (2017) Vol. 76, Iss. 8, pp. 1340-1347
Open Access | Times Cited: 346
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Dominique Baeten, Mikkel Østergaard, James Cheng‐Chung Wei, et al.
Annals of the Rheumatic Diseases (2018) Vol. 77, Iss. 9, pp. 1295-1302
Open Access | Times Cited: 324
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados, et al.
The Lancet (2018) Vol. 392, Iss. 10163, pp. 2441-2451
Open Access | Times Cited: 303
Interleukin 17 Family Cytokines: Signaling Mechanisms, Biological Activities, and Therapeutic Implications
Leticia Monin, Sarah L. Gaffen
Cold Spring Harbor Perspectives in Biology (2017) Vol. 10, Iss. 4, pp. a028522-a028522
Open Access | Times Cited: 292
Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition
Jose U. Scher, Alexis Ogdie, Joseph F. Merola, et al.
Nature Reviews Rheumatology (2019) Vol. 15, Iss. 3, pp. 153-166
Closed Access | Times Cited: 288
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
Andrew Blauvelt, Kristian Reich, Tsen‐Fang Tsai, et al.
Journal of the American Academy of Dermatology (2016) Vol. 76, Iss. 1, pp. 60-69.e9
Closed Access | Times Cited: 282
RORγt inhibition selectively targets IL-17 producing iNKT and γδ-T cells enriched in Spondyloarthritis patients
Koen Venken, Peggy Jacques, Céline Mortier, et al.
Nature Communications (2018) Vol. 10, Iss. 1
Open Access | Times Cited: 279
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
Atul Deodhar, P. J. Mease, Iain B. McInnes, et al.
Arthritis Research & Therapy (2019) Vol. 21, Iss. 1
Open Access | Times Cited: 258
Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
J. Braun, Xenofon Baraliakos, Atul Deodhar, et al.
Annals of the Rheumatic Diseases (2016) Vol. 76, Iss. 6, pp. 1070-1077
Open Access | Times Cited: 241
Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview
Claudia Schinocca, Chiara Rizzo, Serena Fasano, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 241
Th17 plasticity and its relevance to inflammatory bowel disease
Aito Ueno, Louisa Jeffery, Taku Kobayashi, et al.
Journal of Autoimmunity (2017) Vol. 87, pp. 38-49
Closed Access | Times Cited: 240
Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs
Georg Schett, Iain B. McInnes, Markus F. Neurath
New England Journal of Medicine (2021) Vol. 385, Iss. 7, pp. 628-639
Open Access | Times Cited: 238
Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy
Sandra Rayego‐Mateos, José Luis Morgado‐Pascual, Lucas Opazo-Ríos, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 11, pp. 3798-3798
Open Access | Times Cited: 222
Axial spondyloarthritis
Victoria Navarro‐Compán, Alexandre Sepriano, Bassel Elzorkany, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 12, pp. 1511-1521
Closed Access | Times Cited: 221
Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders
Patrizia Fasching, Martin Stradner, W. Graninger, et al.
Molecules (2017) Vol. 22, Iss. 1, pp. 134-134
Open Access | Times Cited: 217
Page 1 - Next Page

Scroll to top